EMERALD‑3 Trial Shows Benefit of Dual Immunotherapy–Based Strategy in Embolization‑Eligible Liver Cancer

As reported on PharmaBiz, a novel treatment strategy combining dual immunotherapy, targeted therapy, and transarterial chemoembolization (TACE) has demonstrated meaningful clinical benefit for patients with unresectable hepatocellular carcinoma (HCC), according…

Continue Reading EMERALD‑3 Trial Shows Benefit of Dual Immunotherapy–Based Strategy in Embolization‑Eligible Liver Cancer

Illumina and Labcorp Deepen Collaboration to Broaden Access to Precision Oncology Testing

As reported on PharmaBiz, Illumina and Labcorp have announced an expanded strategic collaboration aimed at accelerating precision oncology by applying next-generation sequencing (NGS) technologies more broadly across cancer care. The…

Continue Reading Illumina and Labcorp Deepen Collaboration to Broaden Access to Precision Oncology Testing

Roche’s Phase III persevERA Trial of Giredestrant Misses Primary Endpoint in Advanced ER-Positive Breast Cancer

As covered on PharmaBiz, Roche has reported topline results from the phase III persevERA Breast Cancer study, which evaluated the oral selective oestrogen receptor degrader (SERD) giredestrant in combination with…

Continue Reading Roche’s Phase III persevERA Trial of Giredestrant Misses Primary Endpoint in Advanced ER-Positive Breast Cancer

Datroway Receives U.S. Priority Review for First‑Line Treatment of Metastatic Triple‑Negative Breast Cancer

In a recent statement by AstraZeneca, AstraZeneca and Daiichi Sankyo’s antibody‑drug conjugate Datroway (datopotamab deruxtecan) has been granted Priority Review by the U.S. Food and Drug Administration (FDA) for use…

Continue Reading Datroway Receives U.S. Priority Review for First‑Line Treatment of Metastatic Triple‑Negative Breast Cancer

Swiss Biotechs Gain Momentum with FDA Fast Track Option for Palmoplantar Pustulosis

A trio of Swiss biotechnology companies is advancing diverse therapeutic pipelines, with recent developments spanning inflammatory skin disease, immune‑mediated hair loss, and hard‑to‑treat cancers. Together, these milestones highlight how distinct…

Continue Reading Swiss Biotechs Gain Momentum with FDA Fast Track Option for Palmoplantar Pustulosis

New Immunotherapy Strategy Targets Tumor ‘Bodyguards,’ Shows Powerful Results in Preclinical Cancer Models

As reported on ScienceDaily, a research team at the Icahn School of Medicine at Mount Sinai has unveiled a novel immunotherapy that tackles metastatic cancer by attacking the tumor’s protective…

Continue Reading New Immunotherapy Strategy Targets Tumor ‘Bodyguards,’ Shows Powerful Results in Preclinical Cancer Models

Why Most Cancer Patients Don’t Benefit from Modern Immunotherapy, And Why Your Heart Medication Might Change That

Cancer immunotherapy represents one of modern medicine's greatest achievements, yet it's also one of its most frustrating paradoxes: a treatment that works miracles for some patients fails silently for others.…

Continue Reading Why Most Cancer Patients Don’t Benefit from Modern Immunotherapy, And Why Your Heart Medication Might Change That

A 20-Year Journey Through Prostate Cancer, Recurrence, and Modern ADT: A Patient’s Perspective on What Clinicians Need to Know

Twenty years is a long time to believe a cancer chapter has closed. For two decades after my radical prostatectomy, I lived with the quiet confidence of someone who had…

Continue Reading A 20-Year Journey Through Prostate Cancer, Recurrence, and Modern ADT: A Patient’s Perspective on What Clinicians Need to Know

ImmunityBio Reports Encouraging Evidence That ANKTIVA Enhances Immune Recovery in NSCLC When Paired With Checkpoint Inhibitors

As reported on Business Wire, ImmunityBio has released new clinical findings suggesting that its interleukin‑15 superagonist, ANKTIVA® (nogapendekin alfa inbakicept), may help restore immune function and improve survival outcomes in…

Continue Reading ImmunityBio Reports Encouraging Evidence That ANKTIVA Enhances Immune Recovery in NSCLC When Paired With Checkpoint Inhibitors

AstraZeneca’s LATIFY Trial Misses Primary Endpoint in Previously Treated Advanced NSCLC

As reported on PharmaBiz, AstraZeneca’s phase III LATIFY trial has fallen short of its primary objective, with the combination of the ATR inhibitor ceralasertib and the PD‑L1 inhibitor Imfinzi (durvalumab)…

Continue Reading AstraZeneca’s LATIFY Trial Misses Primary Endpoint in Previously Treated Advanced NSCLC

“The Aftermath: Nobody Told Me This Part Would Hurt Too: – Megan’s Fight Against Non-Hodgkin’s Lymphoma

Editor's Note: Patient Worthy is proud to share this story from our friends at Elephants & Tea. To see the story in its original format, please click here. “Well, good…

Continue Reading “The Aftermath: Nobody Told Me This Part Would Hurt Too: – Megan’s Fight Against Non-Hodgkin’s Lymphoma